<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40692549</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2048-6790</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Journal of nutritional science</Title><ISOAbbreviation>J Nutr Sci</ISOAbbreviation></Journal><ArticleTitle>Randomised controlled trial: nutritional supplements to relieve irritable bowel syndrome symptoms by targeting the gut microbiota.</ArticleTitle><Pagination><StartPage>e46</StartPage><MedlinePgn>e46</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e46</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1017/jns.2025.10021</ELocationID><Abstract><AbstractText>In individuals with irritable bowel syndrome (IBS), eliminating dietary triggers can alleviate symptoms but may lead to nutrient deficiencies and overall health decline. Although various nutritional supplements show promising results in relieving IBS symptoms due to their potential to alter the microbiome, conclusive scientific evidence remains lacking. This exploratory study aims to assess the bifidogenic properties of four nutritional supplement interventions and their impact on IBS-symptoms, faecal microbiota composition, faecal short-chain fatty acid (SCFA) concentrations, stool pattern, and quality of life (QoL), compared to a placebo control. Seventy subjects with IBS, meeting the ROME IV criteria, participated in this randomised, double-blind, placebo-controlled parallel intervention study. Subjects were assigned to one of the four treatment groups, receiving either resistant starch, pea fibre, chondroitin sulfate, protein hydrolysate, or placebo daily for four weeks. Daily reports on stool pattern and gastrointestinal complaints were collected. Stool samples and questionnaires on dietary intake, symptom severity, QoL, and anxiety and depression were collected at baseline and after the 4-week intervention. The results show no significant increase in <i>Bifidobacterium</i> abundance or faecal SCFA levels after the 4-week intervention with any of the four nutritional supplement interventions. While some improvements in symptom severity and QoL were observed within-groups, these were not significantly different from changes observed with placebo. In conclusion, the tested nutritional supplements did not increase <i>Bifidobacterium</i> abundance in subjects with IBS within four weeks. Furthermore, we conclude that future studies should consider a run-in period and a larger sample size to study improvements in IBS symptoms.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van den Belt</LastName><ForeName>Maartje</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9679-6925</Identifier><AffiliationInfo><Affiliation>Wageningen Food &amp; Biobased Research, Wageningen University &amp; Research, Wageningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhuang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Laboratory of Microbiology, Wageningen University &amp; Research, Wageningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janssen Duijghuijsen</LastName><ForeName>Lonneke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Wageningen Food &amp; Biobased Research, Wageningen University &amp; Research, Wageningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zoetendal</LastName><ForeName>Erwin G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Laboratory of Microbiology, Wageningen University &amp; Research, Wageningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witteman</LastName><ForeName>Ben</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Human Nutrition and Health, Wageningen University &amp; Research, Wageningen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gastroenterology and Hepatology Department, Hospital Gelderse Vallei, Ede, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Roos</LastName><ForeName>Nicole M</ForeName><Initials>NM</Initials><Identifier Source="ORCID">0000-0002-3655-1678</Identifier><AffiliationInfo><Affiliation>Division of Human Nutrition and Health, Wageningen University &amp; Research, Wageningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vos</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Wageningen Food &amp; Biobased Research, Wageningen University &amp; Research, Wageningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smidt</LastName><ForeName>Hauke</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Microbiology, Wageningen University &amp; Research, Wageningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Wit</LastName><ForeName>Nicole J W</ForeName><Initials>NJW</Initials><AffiliationInfo><Affiliation>Wageningen Food &amp; Biobased Research, Wageningen University &amp; Research, Wageningen, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Nutr Sci</MedlineTA><NlmUniqueID>101590587</NlmUniqueID><ISSNLinking>2048-6790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005232">Fatty Acids, Volatile</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004043">Dietary Fiber</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011492">Protein Hydrolysates</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="Y">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005232" MajorTopicYN="N">Fatty Acids, Volatile</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001644" MajorTopicYN="N">Bifidobacterium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004043" MajorTopicYN="N">Dietary Fiber</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011492" MajorTopicYN="N">Protein Hydrolysates</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BMI, Body Mass Index</Keyword><Keyword MajorTopicYN="N">Bifidobacterium</Keyword><Keyword MajorTopicYN="N">EMA, Ecological Momentary Assessment</Keyword><Keyword MajorTopicYN="N">FDR, False Discovery Rate</Keyword><Keyword MajorTopicYN="N">FFQ, Food Frequency Questionnaire</Keyword><Keyword MajorTopicYN="N">Functional foods</Keyword><Keyword MajorTopicYN="N">HADS, Hospital Anxiety and Depression Score</Keyword><Keyword MajorTopicYN="N">IBS, Irritable bowel Syndrome</Keyword><Keyword MajorTopicYN="N">IBS-C, IBS with predominant constipation</Keyword><Keyword MajorTopicYN="N">IBS-D, IBS with predominant diarrhoea</Keyword><Keyword MajorTopicYN="N">IBS-M, IBS with a mix of constipation and diarrhoea</Keyword><Keyword MajorTopicYN="N">IBS-SSS, Irritable Bowel Syndrome Severity Scoring System</Keyword><Keyword MajorTopicYN="N">IBS-U, IBS with no specific stool pattern</Keyword><Keyword MajorTopicYN="N">ITT, Intention To Treat</Keyword><Keyword MajorTopicYN="N">Irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">Microbiota</Keyword><Keyword MajorTopicYN="N">PCR, Polymerase Chain Reaction</Keyword><Keyword MajorTopicYN="N">PP, Per protocol</Keyword><Keyword MajorTopicYN="N">QoL, quality of life</Keyword><Keyword MajorTopicYN="N">SCFA, short-chain fatty acids</Keyword><Keyword MajorTopicYN="N">severity</Keyword></KeywordList><CoiStatement>The authors declare not to have conflict of interest. No brand names or specific products were communicated to the study subjects.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>22</Day><Hour>11</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>22</Day><Hour>11</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>22</Day><Hour>4</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40692549</ArticleId><ArticleId IdType="pmc">PMC12278178</ArticleId><ArticleId IdType="doi">10.1017/jns.2025.10021</ArticleId><ArticleId IdType="pii">S2048679025100219</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016;150(6):1262&#x2013;1279.e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">27144617</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy BE, Patel NK. Rome criteria and a diagnostic approach to irritable bowel syndrome. J Clin Med. 2017;6(11):99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5704116</ArticleId><ArticleId IdType="pubmed">29072609</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(22):6759&#x2013;6773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4051916</ArticleId><ArticleId IdType="pubmed">24944467</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7(3):163&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">20101257</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes PA, Fraher MH, Quigley EM. Irritable bowel syndrome: the role of food in pathogenesis and management. Gastroenterol Hepatol (N Y). 2014;10(3):164&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4014048</ArticleId><ArticleId IdType="pubmed">24829543</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohn L, Storsrud S, Tornblom H, Bengtsson U, Simren M. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol. 2013;108(5):634&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">23644955</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijnaarts I, Witteman BJM, Zoetendal EG, Govers C, de Wit NJW, de Roos NM. Subtypes and severity of irritable bowel syndrome are not related to patients&#x2019; self-reported dietary triggers: results from an online survey in Dutch adults. J Acad Nutr Diet. 2021;121(9):1750&#x2013;1762.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">33674208</ArticleId></ArticleIdList></Reference><Reference><Citation>Radziszewska M, Smarkusz-Zarzecka J, Ostrowska L. Nutrition, physical activity and supplementation in irritable bowel syndrome. Nutrients. 2023;15(16):3662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10459186</ArticleId><ArticleId IdType="pubmed">37630852</ArticleId></ArticleIdList></Reference><Reference><Citation>Chassard C, Dapoigny M, Scott KP, et al. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther. 2012;35(7):828&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">22315951</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogius-Kurikka L, Lyra A, Malinen E, et al. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol. 2009;9:95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2807867</ArticleId><ArticleId IdType="pubmed">20015409</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajilic-Stojanovic M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141(5):1792&#x2013;1801.</Citation><ArticleIdList><ArticleId IdType="pubmed">21820992</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittayanon R, Lau JT, Yuan Y, et al. Gut microbiota in patients with irritable bowel syndrome: a systematic review. Gastroenterology. 2019;157(1):97&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">30940523</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Rijnaarts I, Hermes GDA, et al. Fecal microbiota signatures are not consistently related to symptom severity in irritable bowel syndrome. Dig Dis Sci. 2022;67(11):5137&#x2013;5148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9587953</ArticleId><ArticleId IdType="pubmed">35624331</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(10):1044&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>
Pinto-Sanchez MI, Hall GB, Ghajar K, et al. 
Probiotic <i>Bifidobacterium longum</i> NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. Gastroenterology.
2017;153(2):448&#x2013;459.e8.
</Citation><ArticleIdList><ArticleId IdType="pubmed">28483500</ArticleId></ArticleIdList></Reference><Reference><Citation>So D, Whelan K, Rossi M, et al. Dietary fiber intervention on gut microbiota composition in healthy adults: a systematic review and meta-analysis. Am J Clin Nutr. 2018;107(6):965&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">29757343</ArticleId></ArticleIdList></Reference><Reference><Citation>den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013;54(9):2325&#x2013;2340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3735932</ArticleId><ArticleId IdType="pubmed">23821742</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh A, De Vadder F, Kovatcheva-Datchary P, Backhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332&#x2013;1345.</Citation><ArticleIdList><ArticleId IdType="pubmed">27259147</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang F, Wang K, Yang X, Yuan Y, Zhang B. Fibre matrices for enhanced gut health: a mini review. Int J Food Sci Technol. 2023;58(8):1&#x2013;7.</Citation></Reference><Reference><Citation>Mart&#xed;nez I, Kim J, Duffy PR, Schlegel VL, Walter J. Resistant starches types 2 and 4 have differential effects on the composition of the fecal microbiota in human subjects. PLoS One. 2010;5(11):e15046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2993935</ArticleId><ArticleId IdType="pubmed">21151493</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata E, Hotta H, Goto M. The screening method of a bifidogenic dietary fiber extracted from inedible parts of vegetables. J Nutr Sci Vitaminol. 2009;55(4):385&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">19763042</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzola G, Aloisio I, Biavati B, Gioia DD. Development of a synbiotic product for newborns and infants. LWT - Food Sci Technol. 2015;64:727&#x2013;734.</Citation></Reference><Reference><Citation>Liu F, Zhang N, Li Z, et al. Chondroitin sulfate disaccharides modified the structure and function of the murine gut microbiome under healthy and stressed conditions. Sci Rep. 2017;7(1):6783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5533764</ArticleId><ArticleId IdType="pubmed">28754911</ArticleId></ArticleIdList></Reference><Reference><Citation>Shmagel A, Demmer R, Knights D, et al. The effects of glucosamine and chondroitin sulfate on gut microbial composition: a systematic review of evidence from animal and human studies. Nutrients. 2019;11(2):294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6412843</ArticleId><ArticleId IdType="pubmed">30704054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy PJ, Cryan JF, Dinan TG, Clarke G. Irritable bowel syndrome: a microbiome-gut-brain axis disorder? World J Gastroenterol. 2014;20(39):14105&#x2013;14125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4202342</ArticleId><ArticleId IdType="pubmed">25339800</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin HY, Cheng CW, Tang XD, Bian ZX. Impact of psychological stress on irritable bowel syndrome. World J Gastroenterol. 2014;20(39):14126&#x2013;14131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4202343</ArticleId><ArticleId IdType="pubmed">25339801</ArticleId></ArticleIdList></Reference><Reference><Citation>Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13(10):701&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">22968153</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster JA, Rinaman L, Cryan JF. Stress &amp; the gut-brain axis: regulation by the microbiome. Neurobiol Stress. 2017;7:124&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5736941</ArticleId><ArticleId IdType="pubmed">29276734</ArticleId></ArticleIdList></Reference><Reference><Citation>Miclo L, Perrin E, Driou A, et al. Characterization of alpha-casozepine, a tryptic peptide from bovine alpha(s1)-casein with benzodiazepine-like activity. FASEB J. 2001;15(10):1780&#x2013;1782.</Citation><ArticleIdList><ArticleId IdType="pubmed">11481228</ArticleId></ArticleIdList></Reference><Reference><Citation>Benoit S, Chaumontet C, Schwarz J, Cakir-Kiefer C, Tom&#xe9; D, Miclo L. Mapping in mice the brain regions involved in the anxiolytic-like properties of &#x3b1;-casozepine, a tryptic peptide derived from bovine &#x3b1;s1-casein. J Funct Foods. 2017;38:464&#x2013;473.</Citation></Reference><Reference><Citation>Gao PP, Liu HQ, Ye ZW, et al. The beneficial potential of protein hydrolysates as prebiotic for probiotics and its biological activity: a review. Crit Rev Food Sci Nutr. 2023;64(33):13045&#x2013;13057.</Citation><ArticleIdList><ArticleId IdType="pubmed">37811651</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Mujagic Z, Keszthelyi D, Aziz Q, et al. Systematic review: instruments to assess abdominal pain in irritable bowel syndrome. Aliment Pharmacol Ther. 2015;42(9):1064&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">26290286</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrae DA, Patrick DL, Drossman DA, Covington PS. Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients. Health Qual Life Outcomes. 2013;11:208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3895767</ArticleId><ArticleId IdType="pubmed">24330412</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 1998;43(2):400&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">9512138</ArticleId></ArticleIdList></Reference><Reference><Citation>Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">6880820</ArticleId></ArticleIdList></Reference><Reference><Citation>Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29(5):508&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">19053980</ArticleId></ArticleIdList></Reference><Reference><Citation>Salonen A, Nikkil&#xe4; J, Jalanka-Tuovinen J, et al. Comparative analysis of fecal DNA extraction methods with phylogenetic microarray: effective recovery of bacterial and archaeal DNA using mechanical cell lysis. J Microbiol Methods. 2010;81(2):127&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">20171997</ArticleId></ArticleIdList></Reference><Reference><Citation>Parada AE, Needham DM, Fuhrman JA. Every base matters: assessing small subunit rRNA primers for marine microbiomes with mock communities, time series and global field samples. Environ Microbiol. 2016;18(5):1403&#x2013;1414.</Citation><ArticleIdList><ArticleId IdType="pubmed">26271760</ArticleId></ArticleIdList></Reference><Reference><Citation>Apprill A, McNally S, Parsons R, Weber L. Minor revision to V4 region SSU rRNA 806R gene primer greatly increases detection of SAR11 bacterioplankton. Aquat Microb Ecol. 2015;75(2):129&#x2013;137.</Citation></Reference><Reference><Citation>Ramiro-Garcia J, Hermes GDA, Giatsis C, et al. NG-Tax, a highly accurate and validated pipeline for analysis of 16S rRNA amplicons from complex biomes. F1000Res. 2016;5:1791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6419982</ArticleId><ArticleId IdType="pubmed">30918626</ArticleId></ArticleIdList></Reference><Reference><Citation>Poncheewin W, Hermes GDA, Van Dam JCJ, Koehorst JJ, Smidt H, Schaap PJ. NG-Tax 2.0: a semantic framework for high-throughput amplicon analysis. Front Genet. 2020;10:1366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6989550</ArticleId><ArticleId IdType="pubmed">32117417</ArticleId></ArticleIdList></Reference><Reference><Citation>
Leo L, Sudarshan S. microbiome R package. 2017. https://bioconductor.org/packages/release/bioc/html/microbiome.html (Accessed June 2022).</Citation></Reference><Reference><Citation>McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One 2013;8(4):e61217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3632530</ArticleId><ArticleId IdType="pubmed">23630581</ArticleId></ArticleIdList></Reference><Reference><Citation>Kembel SW, Cowan PD, Helmus MR, et al. Picante: R tools for integrating phylogenies and ecology. Bioinformatics. 2010;26(11):1463&#x2013;1464.</Citation><ArticleIdList><ArticleId IdType="pubmed">20395285</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozupone CA, Hamady M, Kelley ST, Knight R. Quantitative and qualitative &#x3b2; diversity measures lead to different insights into factors that structure microbial communities. Appl Environ Microbiol. 2007;73(5):1576&#x2013;1585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1828774</ArticleId><ArticleId IdType="pubmed">17220268</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol. 2005;71(12):8228&#x2013;8235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1317376</ArticleId><ArticleId IdType="pubmed">16332807</ArticleId></ArticleIdList></Reference><Reference><Citation>
Oksanen J, Blanchet FG, Kindt R, et al.  Vegan: Community Ecology Package. R package version 2.0&#x2013;2. 2012. https://cran.r-project.org/web/packages/vegan/vegan.pdf (Accessed July 2022).</Citation></Reference><Reference><Citation>Wickham H. Getting started with ggplot2. In: Wickham H, ed. ggplot2: Elegant Graphics for Data Analysis. Cham: Springer International Publishing; 2016:11&#x2013;31.</Citation></Reference><Reference><Citation>
Kassambara A. rstatix: Pipe-Friendly Framework for Basic Statistical Tests. R package version 0.7.0. 2021. https://github.com/kassambara/rstatix/archive/refs/tags/v0.7.0.tar.gz (Accessed June 2022).</Citation></Reference><Reference><Citation>Dobranowski PA, Stintzi A. Resistant starch, microbiome, and precision modulation. Gut Microbes. 2021;13(1):1926842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8288039</ArticleId><ArticleId IdType="pubmed">34275431</ArticleId></ArticleIdList></Reference><Reference><Citation>
Bush JR, Alfa MJ.
Increasing levels of <i>Parasutterella</i> in the gut microbiome correlate with improving low-density lipoprotein levels in healthy adults consuming resistant potato starch during a randomised trial. BMC Nutr.
2020;6(1):72.
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7731750</ArticleId><ArticleId IdType="pubmed">33303023</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson B, Rossi M, Kanno T, et al. &#x3b2;-Galactooligosaccharide in conjunction with low FODMAP diet improves irritable bowel syndrome symptoms but reduces fecal Bifidobacteria. Am J Gastroenterol. 2020;115(6):906&#x2013;915.</Citation><ArticleIdList><ArticleId IdType="pubmed">32433273</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermes GDA, Reijnders D, Kootte RS, et al. Individual and cohort-specific gut microbiota patterns associated with tissue-specific insulin sensitivity in overweight and obese males. Sci Rep. 2020;10(1):7523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7200728</ArticleId><ArticleId IdType="pubmed">32371932</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N, Forster SC. Microbiota shuns the modern world. Nat Rev Microbiol. 2017;15(12):710.</Citation><ArticleIdList><ArticleId IdType="pubmed">29081498</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnenburg JL, B&#xe4;ckhed F. Diet&#x2013;microbiota interactions as moderators of human metabolism. Nature. 2016;535(7610):56&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5991619</ArticleId><ArticleId IdType="pubmed">27383980</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu HN, Wu H, Chen YZ, Chen YJ, Shen XZ, Liu TT. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: a systematic review and meta-analysis. Dig Liver Dis. 2017;49(4):331&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">28179092</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosman M, Elsenbruch S, Corsetti M, et al. The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(6):459&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">33765447</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>